Loading...
XNAS
GLMD
Market cap3mUSD
Jul 09, Last price  
0.57USD
1D
0.00%
1Q
-23.08%
Jan 2017
-99.91%
IPO
-99.98%
Name

Galmed Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XNAS:GLMD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.89%
Rev. gr., 5y
63.12%
Revenues
0k
0000467,0001,085,0002,038,0000000000
Net income
-10m
L+37.14%
-3,149,000-17,485,000-9,103,000-10,622,000-16,953,000-12,299,000-9,856,000-20,461,000-28,771,000-32,467,000-17,866,000-6,912,000-7,517,000-10,309,000
CFO
-6m
L+7.40%
-3,079,000-2,524,000-9,241,000-8,474,000-12,129,000-12,067,000-9,023,000-14,937,000-26,287,000-32,892,000-18,501,000-6,137,000-5,880,000-6,315,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
URL
http://www.galmedpharma.com
IPO date
Mar 13, 2014
Employees
4
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT